Ajanta Pharma Ltd Q2 FY26: ₹1,354 Cr Revenue, ₹260 Cr Profit & ₹28 Interim Dividend — Margin Revival or Just Another Placebo?
1. At a Glance
If Ajanta Pharma were a person, it would be that disciplined topper who quietly pulls all-nighters while the rest of the class panic-studies the day before exams — and then still humbly says, “Bas theek hi tha.”
For Q2 FY26, the company clocked consolidated revenue of ₹1,354 crore, up 14.1% YoY, while PAT jumped 20.2% YoY to ₹260 crore. Operating margins hovered around 24%, slightly off from their golden 27% in the previous quarter but still healthier than half the pharma pack.
The Board, clearly feeling generous, announced an interim dividend of ₹28 per share, amounting to ₹349.82 crore. Current market cap: ₹31,717 crore, stock P/E: 32.6x, ROE: 24.9%, and ROCE: 32.4% — a report card that screams “I’m not Sun Pharma-rich yet, but I’m definitely the class monitor.”
The stock trades at ₹2,538 — about 17% below its 52-week high — perhaps a post-tax hangover after the August 2025 Income Tax search raid. But hey, if you can walk out of a tax raid and still pay ₹28/share in dividend, that’s what corporate swag looks like.
2. Introduction
In an industry where half the players are still figuring out whether they’re R&D-driven or just R&D-ridden, Ajanta Pharma has managed to strike that rare middle ground — profitable innovation.
Founded in 1973, the Mumbai-based midcap wonder has carved a niche by going where others won’t — niche branded generics in India, low-competition markets abroad, and first-to-market launches that keep its MR teams busier than a D-Mart billing counter on Sunday.
What makes Ajanta interesting isn’t just its product range; it’s their obsession with timing. The company has a knack for entering therapeutic segments early, milking the high-margin window, and exiting before price erosion becomes a pandemic. If timing the market were a pharmaceutical art, Ajanta would’ve patented it by now.
But let’s not forget — FY25 wasn’t entirely antibiotic-clean. US price erosion, freight costs, and an income tax visit (a.k.a. “uninvited audit sleepover”) dented sentiment. Yet the company bounced back faster than your local chemist recovers from an expiry-date mistake.
3. Business Model – WTF Do They Even Do?
If you ever wondered who makes the eye drops, anti-hypertensives, and pain gels your doctor prescribes, chances are Ajanta’s fingerprints are somewhere on that blister pack.
Here’s the breakdown:
India Branded Generics (31% of FY23 revenues): Focused on four high-margin therapeutic areas — Cardiology, Ophthalmology, Dermatology, and Pain Management. Over 500+ products, with nearly half being first-to-market. Basically, the Apple of generic drugs: doesn’t invent molecules but makes them sexier and more profitable.
US Generics (22%): Started from scratch in FY16 and hit ₹828 crore revenue in FY23 with 40 products. Focuses on complex oral solids with extended-release formulations — because simple tablets are for amateurs. Recently, they’ve started trimming exposure due to relentless price erosion (US FDA giveth, US PBMs taketh away).
Rest of World Branded (41%): From the Philippines to Africa, Ajanta sells branded generics with Bollywood-style dominance. They’ve tripled product filings and grown teams by 50% across Asia and Africa.
African Institutional (5%): Once Ajanta’s malaria-slaying division, now reduced to a side hustle thanks to the “lumpy” nature of WHO-funded contracts.
Their mantra? “Smart product selection, superior formulations, and focus.” Basically, R&D that actually earns a salary.
4. Financials Overview
Source table
Metric (₹ Cr)
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
1,354
1,187
1,303
14.1%
3.9%
EBITDA
328
311
351
5.5%
-6.6%
PAT
260
216
255
20.2%
2.0%
EPS (₹)
20.83
17.33
20.44
20.2%
1.9%
If earnings were a prescription, Ajanta’s results are the “take with water, twice daily” kind — steady, safe, and side-effect-free.
Margins are stable, profit growth outpaces sales growth (rare in pharma), and EPS keeps compounding like a mutual fund on steroids.
5. Valuation Discussion – Fair Value Range
Let’s play valuation doctor:
(a) P/E Method: EPS (TTM): ₹77.9 Industry P/E: ~33x → Fair Value Range = ₹77.9 × (28–36) = ₹2,180 – ₹2,800
